Oncology Peer Review On-The-Go: Emerging and Existing Treatment Regimens for Transplant-Ineligible DLBCL
For the “Oncology Peer Review On-The-Go” podcast, CancerNetwork® sat down with Gilles Salles, MD, to discuss different treatment regimens for transplant-ineligible DLBCL in this special edition episode.
In this special episode of the “Oncology Peer Review On-The-Go” podcast, CancerNetwork® spoke with Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, about recently approved and emerging treatment regimens for transplant-ineligible diffuse large B-cell lymphoma (DLBCL).
Salles discussed some of the available treatment options including tafasitamab (Monjuvi), chimeric antigen receptor T-cell therapies, selinexor (Xpovio), and antibody-drug conjugates. He also looked ahead at some of the upcoming research on the horizon, including the B-MIND trial (NCT02763319) investigating tafasitamab or rituximab (Rituxan) plus bendamustine.
Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies
Several lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
